Alpha-Galactosidase ist eine Exoglycosidase, die α-D-Galactose spaltet und zahlreiche Anwendungen in der Medizin-, Biotechnologie-, Lebensmittel- und Pharmaindustrie hat. In dieser Studie wurde eine niedermolekulare saure α-Galactosidase aus den Samen von Puddingapfel identifiziert. Die Reinigung von α-Galactosidase aus dem Rohextrakt entfetteter Samen wurde unter Verwendung von Ammoniumsulfatfraktionierung, hydrophober Wechselwirkung und Gelfiltrationschromatographietechniken erreicht. Die gereinigte Puddingapfel-α-Galactosidase (CaG) wanderte als einzelne Bande in nativer PAGE entsprechend einem Molekulargewicht von ~ 67 kDa und gespaltenen chromogenen, fluorogenen und natürlichen Substraten.
Es wurde gefunden, dass CaG ein Heterodimer mit Untereinheitenmassen von 40 und 30 kDa ist. Die kinetischen Parameter wie KM und Vmax betrugen mit p-Nitrophenyl-α-D-galactopyranosid 0,67 mM bzw. 1,5 U / mg. Galactose, Methyl-α-D-Galactopyranosid und D-Galacturonsäure hemmten die CaG-Aktivität im gemischten Modus. Die CD-Spektralanalyse im fernen UV-Bereich zeigte, dass gereinigtes CaG in seiner Sekundärstruktur überwiegend als Helix (35%), Beta-Faltblätter (16,3%) und Zufallsspulen (32,3%) vorliegt. Diese biochemischen und biophysikalischen Eigenschaften von CaG führen zum Verständnis seiner Primärsequenz und seiner Glykanstrukturen, die schließlich seine neuartigen physiologischen Rollen in Pflanzen und potenziellen industriellen Anwendungen definieren werden.
In diesem Artikel wird der Einfluss von Faktoren auf die Produktinnovation untersucht, die auf der Transformation und Nutzung von Wissen aus den organisationsinternen Beziehungen eines Unternehmens beruhen. Insbesondere analysiert dieses Papier den Einfluss des intraorganisatorischen Sozialkapitals (SC) (d. H. Bestehend aus strukturellen, relationalen und kognitiven Dimensionen) auf die realisierte Absorptionskapazität (RACAP). Darüber hinaus wird die Vermittlerrolle von RACAP in Bezug auf die Beziehung zwischen internem SC und Produktinnovation analysiert. Basierend auf einer Stichprobe von Unternehmen aus der spanischen biotechnologischen und pharmazeutischen Industrie wurden zwei Hypothesen unter Verwendung eines Strukturgleichungsmodells und der PLS-Technik (Partial Least Squares) getestet.
Die Ergebnisse stützen beide Hypothesen, was darauf hindeutet, dass die Entwicklung starker und enger Verbindungen, die auf einem gemeinsamen Verständnis und Vertrauen der Unternehmensmitglieder beruhen, das Unternehmen dazu veranlasst, dynamische Fähigkeiten zur Transformation und Nutzung von extern erworbenem Wissen zu entwickeln, was Innovationen auf der Grundlage der Entwicklung neuer Produkte fördert. Forschungsgrenzen, Implikationen und zukünftige Forschung werden auch von den Autoren des Papiers diskutiert.
Intensive Bitterkeit von Molekülen: Maschinelles Lernen zur Beschleunigung der Wirkstoffentdeckung
Die Arzneimittelentwicklung ist ein langer, teurer und mehrstufiger Prozess, der darauf abzielt, sichere Arzneimittel mit hoher Wirksamkeit zu erzielen. Eine entscheidende Voraussetzung für den Abschluss des Medikationsschemas für orale Medikamente, insbesondere für pädiatrische und geriatrische Bevölkerungsgruppen, ist das Erreichen eines Geschmacks, der die Compliance nicht behindert. Derzeit wird der aversive Geschmack von Arzneimitteln in späten Stadien klinischer Studien getestet. Dies kann zu einer Neuformulierung führen, die möglicherweise dazu führt, dass mehr Tiere für zusätzliche Toxizitätsversuche verwendet werden, die finanziellen Kosten steigen und die Markteinführung verzögert wird.
Hier präsentieren wir BitterIntense, ein Werkzeug für maschinelles Lernen, das Moleküle aufgrund ihrer chemischen Struktur in “sehr bitter” oder “nicht sehr bitter” klassifiziert. Das Modell, das auf chemisch verschiedenen Verbindungen trainiert wurde, weist bei mehreren Testsätzen eine Genauigkeit von über 80% auf. Unsere Ergebnisse legen nahe, dass etwa 25% der Arzneimittel als sehr bitter vorhergesagt werden, wobei die Prävalenz (~ 40%) bei COVID19-Arzneimittelkandidaten und bei mikrobiellen Naturstoffen noch höher ist. Es wird vorausgesagt, dass nur ~ 10% der toxischen Moleküle stark bitter sind, und es wird auch vermutet, dass intensive Bitterkeit nicht mit der Hepatotoxizität von Arzneimitteln korreliert.
Sehr bittere Verbindungen können jedoch kardiotoxischer sein als nicht sehr bittere Verbindungen, die signifikant niedrigere QPlogHERG-Werte besitzen. BitterIntense ermöglicht eine schnelle und einfache Vorhersage der starken Bitterkeit von Verbindungen, die für die Lebensmittel-, Pharma- und Biotechnologieindustrie von Interesse sind. Wir schätzen, dass die Implementierung von BitterIntense oder ähnlichen Tools zu Beginn des Arzneimittelentdeckungsprozesses zu einer Verringerung der Verzögerungen, des Tiergebrauchs und der finanziellen Gesamtbelastung führen kann.

Empfehlungen zur Straffung und Standardisierung der Machbarkeitsbewertungen für Standorte für klinische Studien: Eine ASCO-Forschungserklärung
Machbarkeitsbewertungen (FAs) sind wichtig, um die Standortfähigkeiten für die Durchführung klinischer Studien und ihre Eignung für bestimmte Studien zu ermitteln. Derzeitige FA-Methoden, die von Sponsoren von Biotechnologie- und Pharmaversuchen (Biotech-Pharma) und Auftragsforschungsorganisationen (CROs) verwendet werden, sind jedoch kostspielig, ineffizient, unnötig belastend und ressourcenintensiv. Diese Methoden verzögern den Start der Studie, wirken als Hindernis für die Teilnahme am Standort und verringern letztendlich den rechtzeitigen Zugang der Patienten zu klinischen Studien und neuartigen Behandlungen.
Methoden: Eine ASCO-Task Force wurde einberufen, um die spezifischen Belastungen und Herausforderungen der FA zu bewerten und Empfehlungen zur Verbesserung ihrer Effizienz und Effektivität zu entwickeln. Stakeholder (einschließlich Versuchsstandorte, Biotech-Pharma-Sponsoren und CROs) gaben Einblicke in Herausforderungen und boten Lösungen durch zwei Umfragen und ein persönliches Treffen an.
Die Task Force nutzte das Feedback, um Konsensempfehlungen zur Verbesserung der FAs für klinische Studien in der Onkologie zu formulieren.
Ergebnisse: Drei wichtige Empfehlungen wurden für die Anwendung in allen von Biotech-Pharma gesponserten Studien ermittelt: (1) Implementierung eines optimierten und einheitlichen FA-Prozesses in allen Studien und Sponsoren; (2) Fragen minimieren und standardisieren; und (3) Nutzung von Technologie zur Zentralisierung von FAs, Erleichterung der Kommunikation und Reduzierung von Redundanzen.
Schlussfolgerung: Es ist dringend erforderlich, den derzeitigen FA-Prozess zu verbessern, der kostspielig, inkonsistent, ineffizient, arbeitsintensiv und von ungewisser Wirksamkeit ist.
THERMAL PRINTER PAPER |
GD-PAPER |
CORNING |
1/pk |
EUR 224.4 |
Description: Lab Equipment; Axygen Branded EQ |
Congo Red Powder |
abx090680-5g |
Abbexa |
5 g |
EUR 226.8 |
|
Congo Red "high purity grade" |
80028 |
Biotium |
100MG |
EUR 206.4 |
Description: Minimum order quantity: 1 unit of 100MG |
Congo Red *UltraPure grade* *CAS 573-58-0* |
23056 |
AAT Bioquest |
100 mg |
EUR 138 |
|
Chymase reagent |
30C-CP1129 |
Fitzgerald |
5 units |
EUR 2622 |
Description: Purified native Human Chymase reagent |
Traut's Reagent |
2330-1000 |
Biovision |
|
EUR 418.8 |
BOP reagent |
A7015-100000 |
ApexBio |
100 g |
EUR 240 |
Description: A peptide coupling reagent. Can be used in the preparation of phenyl esters of amino acids which have been shown to be valuable as blocked derivatives of amino acids in the field of peptide synthesis. |
BOP reagent |
A7015-25000 |
ApexBio |
25 g |
EUR 135.6 |
Description: A peptide coupling reagent. Can be used in the preparation of phenyl esters of amino acids which have been shown to be valuable as blocked derivatives of amino acids in the field of peptide synthesis. |
Bradford reagent |
BDE641 |
Bio Basic |
100ml |
EUR 73.21 |
|
DTT (Cleland's reagent) |
DB0058 |
Bio Basic |
5g |
EUR 101.76 |
|
DTNB (Ellman's Reagent) |
DB0113 |
Bio Basic |
5g |
EUR 117.42 |
|
Specimen Preservation Reagent |
DA0970 |
Daan Gene |
100 test/kit |
Ask for price |
PhosphoBlocker Blocking Reagent |
AKR-103 |
Cell Biolabs |
1L |
EUR 393.6 |
Description: Most commercially available Western blot blockers, such as dry milk or serum, are sufficient to block unreactive sites on the membrane. However, they are not designed to preserve phosphoprotein antigens during blotting. Our PhosphoBLOCKER Blocking Reagent provides superior blocking by maximizing signal-to-noise ratio. The PhosphoBLOCKER reagent particluarly excels with very low levels of endogenous phopsphoproteins. |
PhosphoBlocker Blocking Reagent |
AKR-104 |
Cell Biolabs |
4L |
EUR 853.2 |
Description: Most commercially available Western blot blockers, such as dry milk or serum, are sufficient to block unreactive sites on the membrane. However, they are not designed to preserve phosphoprotein antigens during blotting. Our PhosphoBLOCKER Blocking Reagent provides superior blocking by maximizing signal-to-noise ratio. The PhosphoBLOCKER reagent particluarly excels with very low levels of endogenous phopsphoproteins. |
Tri-RNA Reagent |
FATRR-001 |
Favorgen |
100ml |
EUR 283.2 |
Tri-RNA Reagent |
FATRR-002 |
Favorgen |
50ml |
EUR 211.2 |
Tri-RNA Reagent |
FATRR-003 |
Favorgen |
450ml |
EUR 774 |
Biotin reagent (HRP) |
65C-CE0202 |
Fitzgerald |
5 mg |
EUR 292.8 |
Description: HRP conjugated biotin labelling reagent |
Convoy? Transfection Reagent |
1110-1ml |
ACTGene |
|
EUR 409.2 |
BODIPY-Acetylene Reagent |
2594-1 |
Biovision |
|
EUR 248.4 |
BODIPY-Acetylene Reagent |
2594-5 |
Biovision |
|
EUR 810 |
Griess Reagent Kit |
30100 |
Biotium |
1KIT |
EUR 178.8 |
Description: Minimum order quantity: 1 unit of 1KIT |
BSA (Reagent Grade) |
30-AB79 |
Fitzgerald |
1 kg |
EUR 1862.4 |
Description: Reagent Grade Bovine Serum Albumin (99% pure) |
BSA (Reagent Grade) |
30-AB81 |
Fitzgerald |
200 grams |
EUR 571.2 |
Description: Reagent Grade Sulphydryl Blocked BSA (99% pure) |
Bradford Dye Reagent |
0209R |
AthenaES |
100 ml |
EUR 157.2 |
EL Transfection Reagent |
20-abx098880 |
Abbexa |
|
|
|
Mycoplasma Prevention Reagent |
20-abx098886 |
Abbexa |
|
|
|
Girard's reagent T |
20-abx184099 |
Abbexa |
|
|
|
FcR blocking Reagent |
20-abx290024 |
Abbexa |
|
|
|
Detection Reagent A |
abx296004-120ul |
Abbexa |
120 ul |
EUR 385.2 |
|
Mycoplasma Prevention Reagent |
20-abx298005 |
Abbexa |
|
|
|
HAMA blocking reagent |
85R-1001 |
Fitzgerald |
1 gram |
EUR 2368.8 |
Description: HAMA Blocking Reagent for use in immunoassays such as ELISA |
HAMA blocking reagent |
85R-1001P |
Fitzgerald |
1 gram |
EUR 2628 |
Description: HAMA Blocking Reagent for use in immunoassays such as ELISA |
HAMA blocking reagent |
85R-1003 |
Fitzgerald |
1 gram |
EUR 2368.8 |
Description: HAMA Blocking Reagent for use in immunoassays such as Rapid Tests |
HAMA blocking reagent |
85R-1014 |
Fitzgerald |
50 mg |
EUR 230.4 |
Description: HAMA blocking reagent for use in assays specific for clinical false positive samples |
HAMA blocking reagent |
85R-1025 |
Fitzgerald |
50 mg |
EUR 230.4 |
Description: HAMA blocking reagent for use in immunoassays |
HAMA blocking reagent |
85R-1026 |
Fitzgerald |
50 mg |
EUR 230.4 |
Description: HAMA blocking reagent for use in immunoassays |
Biolipidure-1002-Reagent |
Biolipidure-1002-10 |
Cusabio |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-1002-Reagent is a synthetic amphoteric polymer that can be substituted for BSA in tubidimetric immunoassays. Biolipidure-1002 is an excellent blocker and also enhances assay sensitivity. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-1002-Reagent |
Biolipidure-1002-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-1002-Reagent is a synthetic amphoteric polymer that can be substituted for BSA in tubidimetric immunoassays. Biolipidure-1002 is an excellent blocker and also enhances assay sensitivity. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-103-Reagent |
Biolipidure-103-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-103-Reagent is a synthetic amphoteric polymer that can be substituted for BSA. It has been shown to enhance signals in rapid tests, western blots, and other similar immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-103-Reagent |
Biolipidure-103-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-103-Reagent is a synthetic amphoteric polymer that can be substituted for BSA. It has been shown to enhance signals in rapid tests, western blots, and other similar immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-1201-Reagent |
Biolipidure-1201-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-1201 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-1201-Reagent |
Biolipidure-1201-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-1201 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-1301-Reagent |
Biolipidure-1301-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-1301 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-1301-Reagent |
Biolipidure-1301-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-1301 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-203-Reagent |
Biolipidure-203-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-203 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-203 has been shown to enhance signal strength by improving signal-to-noise in ELISAs, EIAs, and related immunoassays. It also functions as an effective blocker and stabilizer in these assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-203-Reagent |
Biolipidure-203-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-203 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-203 has been shown to enhance signal strength by improving signal-to-noise in ELISAs, EIAs, and related immunoassays. It also functions as an effective blocker and stabilizer in these assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-206-Reagent |
Biolipidure-206-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-206 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-206 enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-206-Reagent |
Biolipidure-206-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-206 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-206 enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-405-Reagent |
Biolipidure-405-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-405 Reagent is a synthetic anionic polymer that can be used to enhance immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-405-Reagent |
Biolipidure-405-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-405 Reagent is a synthetic anionic polymer that can be used to enhance immunochromatographic assays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-502-Reagent |
Biolipidure-502-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-502 Reagent is a synthetic cationic polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-502-Reagent |
Biolipidure-502-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-502 Reagent is a synthetic cationic polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-702-Reagent |
Biolipidure-702-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-702 Reagent is a synthetic amphoteric polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-702-Reagent |
Biolipidure-702-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-702 Reagent is a synthetic amphoteric polymer. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-802-Reagent |
Biolipidure-802-10 |
Biolipidure |
10mL |
EUR 235.2 |
|
Description: The Biolipidure-802 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-802 generally enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, Rapid-test, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
Biolipidure-802-Reagent |
Biolipidure-802-100 |
Biolipidure |
100mL |
EUR 1467.6 |
|
Description: The Biolipidure-802 Reagent is a synthetic amphoteric polymer that can be substituted for BSA. Biolipidure-802 generally enhances signal strength, functions as an effective blocker, and stabilizes proteins and antibodies in ELISAs, EIAs, Rapid-test, and related immunoassays. Applications include: Immunoassays, Western blots, Immunohistochemistry, Turbidimetric assays, Immunochromatography, and Bead based assays. Benefits include: No lot to lot variation, No animal derived materials, Non-specific adsorption suppression, Stabilization of immobilized antibody, Stabilization of enzyme-antibody conjugate, Enzyme-substrate reaction enhancement and aggregation reaction enhancement |
LP4K Transfection Reagent |
LP4K |
GenTarget |
1.0 ml / vial |
EUR 364.8 |
Description: Lipid based transfection reagent for large plasmid and multiple plasmid transfection in both adhesive and suspenstion cell types. |
Ethyl acetate Reagent |
EC4600 |
Bio Basic |
1L |
EUR 94.8 |
|
n-Heptane Reagent |
HC5400 |
Bio Basic |
1L |
EUR 94.8 |
|
PureFection Transfection Reagent |
LV750A-1 |
SBI |
1 ml |
EUR 430.8 |
|
ExFect2000 Transfection Reagent |
T202-01 |
Vazyme |
0.5 ml |
EUR 272.4 |
Alle Beteiligten können von der Umsetzung dieser Empfehlungen profitieren, die darauf abzielen, die Belastungen zu minimieren und sicherzustellen, dass mehr Studienorte und Patienten rechtzeitig Zugang zu klinischen Onkologie-Studien haben. Um eine sinnvolle Wirkung zu erzielen, ist die Annahme und konsequente Umsetzung dieser Empfehlungen in allen Studien, Sponsoren, CROs und Standorten von entscheidender Bedeutung.